Stifel Nicolaus Lowers Elanco Animal Health (NYSE:ELAN) Price Target to $18.00

Elanco Animal Health (NYSE:ELAN) had its price target decreased by investment analysts at Stifel Nicolaus from $20.00 to $18.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 52.03% from the stock’s current price.

Other analysts have also recently issued reports about the company. Leerink Partners began coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target for the company. Barclays raised their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. UBS Group started coverage on Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective on the stock. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Finally, Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $16.43.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock traded down $0.08 during midday trading on Tuesday, hitting $11.84. The company had a trading volume of 748,455 shares, compared to its average volume of 3,501,568. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock has a market cap of $5.85 billion, a PE ratio of 29.60, a P/E/G ratio of 2.03 and a beta of 1.41. The business’s 50 day simple moving average is $12.75 and its two-hundred day simple moving average is $13.61. Elanco Animal Health has a 1-year low of $11.40 and a 1-year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period last year, the firm earned $0.18 EPS. The firm’s revenue for the quarter was down 3.6% compared to the same quarter last year. As a group, equities analysts predict that Elanco Animal Health will post 0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently bought and sold shares of ELAN. Commerce Bank grew its holdings in Elanco Animal Health by 2.2% during the 3rd quarter. Commerce Bank now owns 35,114 shares of the company’s stock valued at $516,000 after buying an additional 741 shares in the last quarter. HBK Sorce Advisory LLC lifted its holdings in Elanco Animal Health by 9.4% in the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after acquiring an additional 1,107 shares during the period. Keene & Associates Inc. boosted its position in Elanco Animal Health by 5.7% in the 3rd quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock worth $337,000 after purchasing an additional 1,240 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after purchasing an additional 1,361 shares in the last quarter. Finally, M&T Bank Corp boosted its holdings in Elanco Animal Health by 5.9% during the third quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock worth $388,000 after buying an additional 1,464 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.